Acute Liver Failure During Pirfenidone Treatment Triggered by Co‐Medication With Esomeprazole
Andreas Benesic, Kowcee Jalal, Alexander L. Gerbes – 29 April 2019
Letter to the Editor: Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures
Guandou Yuan, Jiangfa Li, Shuiping Yu, Xiaoping Chen, Songqing He – 29 April 2019
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
Amanda Cheung, Brent A. Neuschwander‐Tetri, David E. Kleiner, Elmer Schabel, Mary Rinella, Stephen Harrison, Vlad Ratziu, Arun J. Sanyal, Rohit Loomba, Sophie Jeannin Megnien, Richard Torstenson, Veronica Miller, on behalf of the Liver Forum Case Definitions Working Group – 29 April 2019 – Identifying effective therapies for nonalcoholic steatohepatitis (NASH) with fibrosis is a pressing challenge, with 1%‐2% of the population in developed nations at risk of developing NASH cirrhosis and its complications.
Sarcopenia in Cirrhosis: Looking Beyond the Skeletal Muscle Loss to See the Systemic Disease
Rahima A. Bhanji, Aldo J. Montano‐Loza, Kymberly D. Watt – 29 April 2019 – Sarcopenia is a common complication of cirrhosis and is defined as a progressive and generalized loss of skeletal muscle mass, strength, and function. Sarcopenia is associated with poor prognosis and increased mortality. How sarcopenia and muscle wasting relate to such poor outcomes requires looking beyond the overt muscle loss and at this entity as a systemic disease that affects muscles of vital organs including cardiac and respiratory muscles.
Reply
Patrick Starlinger, David Pereyra, Matthias Hackl, Alice Assinger – 29 April 2019
Letter to the Editor: The Kynurenine Pathway in Hepatic Cirrhosis
Abdulla Badawy – 29 April 2019
Acute Intermittent Porphyria: Novel Etiologic and Pathogenic Therapies Based on RNA Transfer to the Liver
Jesus Prieto, Gloria Gonzalez‐Aseguinolaza – 26 April 2019
LiverLearning®: 2019 Webinar: Liver Lesions 101
This session will cover principles of imaging characteristics of benign and malignant hepatic lesions. Attendees will also receive an overview of the Liver Imaging Reporting and Data System (LI-RADs) for imaging findings in liver lesions and common biomarkers associated with hepatocellular carcinoma. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .
Influence of Fat on Differential Receptor Interacting Serine/Threonine Protein Kinase 1 Activity Leading to Apoptotic Cell Death in Murine Liver Ischemia Reperfusion Injury Through Caspase 8
Vasantha L. Kolachala, Sirish K. Palle, Ming Shen, Asha Shenoi, Dmitry M. Shayakhmetov, Nitika A. Gupta – 25 April 2019 – Current understanding is that receptor interacting serine/threonine protein kinase 1 (RIPK1) can lead to two distinct forms of cell death: RIPK3‐mediated necroptosis or caspase 8 (Casp8)‐mediated apoptosis. Here, we report that RIPK1 signaling is indispensable for protection from hepatocellular injury in a steatotic liver undergoing ischemia reperfusion injury (IRI) but not in the lean liver.